**HIV PEP Guidelines after Sexual Assault**  
Harborview Medical Center  
January 2015

**Initial risk assessment** and discussion with patient about risk and PEP is by clinician who does exam (SANE, Ob-Gyn resident, pediatrics resident.)

**ED Medicine attending** meets with all patients in “Low to moderate risk” category, and with any patient in other risk categories who wishes to talk about or consider HIV PEP.

**Follow-up:** All patients who start PEP will have follow-up through Madison Clinic. Leave voice message with Madison Clinic PCC (744-5155) who will arrange appointment.

**Medication:** Patient needs 5 days of medication in hand when leaving ED. Dispense from Pyxis.

<table>
<thead>
<tr>
<th>Risk factors of assailant</th>
<th>Lowest risk</th>
<th>Very low risk</th>
<th>Low to moderate risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV PEP not indicated</td>
<td>Option of PEP should be discussed with patient by medical provider (SANE). PEP may be prescribed if patient wishes after full discussion of risks/benefits</td>
<td>Recommendation for PEP should be discussed with patient, with full discussion of risks and benefits</td>
</tr>
<tr>
<td></td>
<td>Assailant is: Man who has sex with women OR Unknown risk factors</td>
<td>Assailant is: Man known or suspected HIV positive (most important factor) Man who has sex with men (HIV prevalence 12-15%) Known IV drug use (HIV prevalence ~2%) (prevalence in King County)</td>
<td></td>
</tr>
<tr>
<td>Risk factors of contact</td>
<td>Ongoing unprotected sexual contact (e.g. intimate partner) No semen to mucosal or wound contact</td>
<td>Semen to mucosal contact, one assailant</td>
<td>Semen to mucosal contact, 2 or more assailants Victim is man assaulted by man Victim has grossly visible vaginal or anal tears Exposure semen to rectum Exposure blood to mucosa Exposure blood to open wound</td>
</tr>
<tr>
<td>Time since contact</td>
<td>PEP must be initiated within 72 hours of exposure</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| HIV PEP Regimen           | PEP not indicated | Risk factor is used to help determine need but regimen does not change based on risk factor | **Updated Regimen:** for any patient requesting HIV PEP  
*Truvada 1 tab po daily plus Raltegravir 400mg BID*  
First 5 days of 28 day course is given in ED  
Full course is 28 days  
Reevaluate at Madison Clinic follow-up |
| Patient Ed                | Use "Information about HIV for Patients” attached Use condoms for consensual relations for 6 months |
| Discussion with patient   | Advise HIV serology may be obtained at f/u medical, 6 wks, 3 and 6 months | ED medicine attending meets patient to discuss PEP if patient is interested Advise: HIV serology should be obtained at 6 wks, 3 and 6 mo If using Antibody/Antigen testing, testing done at 6 weeks and 16 weeks |
|                           | ED Medicine Attending meets all patients in this risk category to discuss HIV PEP |
If patient is appropriate candidate for medication, discuss:

- 28 days medication course needed.
- 5 days of medication will be provided in ED.
- Must come to Madison Clinic appointment within 4 days for evaluation of medication and decision to complete course (see below for how to arrange appt)
- Costs: Crime Victims Compensation may cover cost medication, but only if patient applies for CVC (to qualify pt must cooperate with law enforcement, assault must have occurred in Washington state.). Patient may qualify for charity care, or insurance may cover costs. Med should be obtained at HMC unless pt has insurance.

Baseline labs if patient starts PEP

- Pregnancy test – if positive, Truvada, and Raltegravir are safe in pregnancy. Weigh the risks and benefits
- Urine NAAT for chlamydia and gonorrhea
- HIV antibody/antigen
- CBC platelets
- Creatinine
- Liver function panel (Hepatic panel A)
- RPR

Medications

Prescribe usual post-exposure medications: Azithromycin 1 gm, Cefixime 400 mg (Ceftriaxone 250 mg IM for MSM patients) and Hepatitis B vaccine if not previously fully immunized. Levonorgestrel emergency contraception as indicated.

Standard regimen: Truvada 1 tablet daily (tenofovir 300 mg + emtricitabine 200 mg) + Raltegravir (brand name Isentress) 400 mg BID

- Generally well-tolerated
- May cause nausea, vomiting, diarrhea, flatulence, headache, renal impairment
- Rare but serious lactic acidosis and hepatic steatosis
- Safe in pregnancy (Category B).
- There are potential significant interactions with rifampin
- May cause diarrhea, nausea, vomiting
- Discuss before administering to patients with
  - Hx of liver problems
  - Hx of rhabdomyolysis or myopathy
  - Increased creatinine kinase
  - Hx of PKU (Raltegravir chewables contain phenylalanine)

Consult with infectious disease specialist to choose alternate meds if source patient is taking antiretroviral.

May call HIV MedCon (attending provider) if any questions regarding treatment

Providing initial doses

- Provide initial 5-day supply from HMC Pharmacy.

Follow-up

For sexual assault patients only
☐ TC to Madison clinic to inform of pt’s name and need for follow up visit (confirm correct contact number of patient to leave on Madison clinic voice mail)
☐ Medical follow-up will be at Madison (initially in 2-4 days, and 6 weeks)
☐ All patients will get social work outreach call from HCSATS
☐ Counseling follow-up will be at HCSATS (if patient wishes)

Resources on drug interactions: Harborview Madison Clinic Pharmacy (206-744-5151)
http://depts.washington.edu/madclin/pharmacy/drugs/index.html, and
http://www.hiv-druginteractions.org/

This guideline was developed and approved by:

Amy Baernstein MD  Attending physician Emergency Department Harborview Medical Center. Associate Professor, Medicine/General Internal Medicine University of Washington.

Shireesha Dhanireddy MD  Attending physician Madison Clinic Harborview Medical Center Associate Professor, Allergy & Infectious Diseases, University of Washington.

Robert Harrington MD  Professor Allergy and Infectious Disease University of Washington, Madison Clinic Harborview Medical Center

Naomi Sugar MD  Medical Director, Harborview Center for Sexual Assault and Traumatic Stress. Clinical Professor Pediatrics, University of Washington.
Information for Providers

Risk of Transmission

Do not over-prescribe HIV PEP
Do not prescribe PEP if blood contacted only intact skin.
Do not prescribe PEP for exposures to:

- Saliva (unless visibly bloody)
- Tears
- Feces
- Nasal secretions

...even if these contacted mucous membrane or non-intact skin.

Do not prescribe PEP for bites, unless source person’s mouth was bloody AND exposed person’s skin was visibly broken.

Estimated per-act for acquisition of HIV from HIV + source, by exposure route

<table>
<thead>
<tr>
<th>Action</th>
<th>Predicted conversions per 10,000 acts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood transfusion</td>
<td>9000</td>
</tr>
<tr>
<td>Needle sharing</td>
<td>67 (0.67 per 100 exposures with HIV+ source)</td>
</tr>
<tr>
<td>Receptive anal intercourse</td>
<td>50</td>
</tr>
<tr>
<td>Needle stick</td>
<td>30</td>
</tr>
<tr>
<td>Receptive penile-vaginal intercourse</td>
<td>10 (0.1 per 100 exposures with HIV + source)</td>
</tr>
<tr>
<td>Blood to mucous membranes</td>
<td>9</td>
</tr>
<tr>
<td>Insertive anal intercourse</td>
<td>6.5</td>
</tr>
<tr>
<td>Insertive penile vaginal intercourse</td>
<td>5</td>
</tr>
<tr>
<td>Receptive oral intercourse</td>
<td>1 (0.01 per 100 exposures with HIV+ source)</td>
</tr>
<tr>
<td>Man receiving oral sex</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Risk that source patient is HIV+ (for King County)

- General population: < 1%
- Incarcerated men ~ 1%
- Injection drug users 2%
- Men who have sex with men: 12-15%
- Man who has sex with men and and injection drug use: 22%

References

1. CDC Antiretroviral Postexposure Prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR Reports and recommendations 2005; 54 (No. RR-2).
2. CDC Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis 2005 ; Vol. 54 (No. RR-9)
4. Wiebe ER, Comay SE, McGregor M, Ducceschi S. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months’ experience in a sexual assault service. CMAJ. 2000 Mar 7;162(5):641-5.
Case Examples

1. Woman assaulted by male acquaintance, risk factors of male unknown. Penile-vaginal and penile-oral contact, no condom, no visible genital anal injuries.
   
   **Assessment:** Very low risk
   
   **Action:** Option of PEP should be discussed with patient
   
   **Who:** By medical provider (SANE), ED medicine attending if patient wishes medication.
   
   **Treatment:** PEP may be prescribed if patient wishes after full discussion of risks/benefits. Basic regimen.

2. Woman assaulted by male acquaintance, risk factors of male unknown. Penile-vaginal, penile-oral, and penile-anal contact, no condom, no visible genital anal injuries.
   
   **Assessment:** Low to moderate risk.
   
   **Action:** Recommendation for PEP should be discussed with patient, with full discussion of risks and benefits.
   
   **Who:** Initial discussion by primary examiner, ED Medicine attending should meet with patient to discuss.
   
   **Treatment:** Basic regimen is appropriate, depending on clinician judgment and patient preference.

3. Woman assaulted by male acquaintance, Man thought to be an IV drug user, unknown other risk factors. Penile vaginal contact only
   
   **Assessment:** Low to moderate risk
   
   **Action:** Recommendation for PEP should be discussed with patient, with full discussion of risks and benefits.
   
   **Who:** Initial discussion by primary examiner, ED Medicine attending should meet with patient to discuss.
   
   **Treatment:** Basic regimen OR expanded regimen may be appropriate, depending on clinician judgment and patient preference.

4. Woman assaulted by 2 males 4 days prior to exam
   
   **Assessment:** outside of time frame for HIV PEP
   
   **Action:** Discuss with patient
   
   **Who:** Initial discussion by primary examiner, ED Medicine attending should meet with patient to discuss if further questions.
   
   **Treatment:** No HIV PEP medication. Recommend baseline, 6 weeks 3 months and 6 month HIV serology. Baseline serology can be done at HCSATS follow-up.

5. Woman assaulted by male 24 hours ago. Penile-oral and penile-vaginal contact, condom used. Visible posterior fourchette tear.
   
   **Assessment:** Low to moderate risk
   
   **Action:** Recommendation for PEP should be discussed with patient, with full discussion of risks and benefits.
   
   **Who:** Initial discussion by primary examiner, ED Medicine attending should meet with patient to discuss.
   
   **Treatment:** Basic regimen appropriate,

   
   **Assessment:** Low to moderate risk (although contact is very low risk, but assailant is likely MSM, risk of HIV in assailant is higher than average)
   
   **Action:** Recommendation for PEP should be discussed with patient, with full discussion of risks and benefits.
   
   **Who:** Initial discussion by primary examiner, ED Medicine attending should meet with patient to discuss.
   
   **Treatment:** Basic regimen OR expanded regimen may be appropriate, depending on clinician judgment and patient preference.

   
   **Assessment:** Low to moderate risk.
   
   **Action:** Recommendation for PEP should be discussed with patient, with full discussion of risks and benefits.
   
   **Who:** Initial discussion by primary examiner, ED Medicine attending should meet with patient to discuss.
Treatment: Basic regimen OR expanded regimen may be appropriate, depending on clinician judgment and patient preference.

INFORMATION ABOUT HIV FOR PATIENTS

HIV (human immunodeficiency virus) is the virus which can cause AIDS. Getting HIV is often a fear that people have after a sexual assault. For most individuals the risk of getting HIV from a sexual assault in Washington State is extremely low.

- For women the risk is less than 1 in 1000.

- An assailant must be infected with HIV in order to transmit it. If the assailant were HIV-infected, it is estimated that there is a less than 3% chance of transmitting it during sexual assault.

- In the Pacific Northwest, the rate of HIV infection in the male population is about 1 to 2%. Most men who have HIV are homosexually active. The rate of HIV infection in injection drug users is approximately 2%.

- Medicines are available which can decrease the risk of acquiring HIV. The medicines must be started within 72 hours of the exposure and taken for 28 days month in order to be effective. These medications can cause mild gastrointestinal symptoms (nausea, diarrhea, fatigue, and muscle aches) and are not recommended in very low risk situations.

- For men who have been sexually assaulted by men there is a higher, although still small chance of getting HIV. About 1 in 7 gay men in Seattle are HIV+, but the risk of HIV transmission, even without condoms is around 1%. Under these circumstances, the risks and benefits of preventive medicine should be discussed with a health care provider.

The risk of HIV infection is quite low. But this was not a risk that you chose to take.

If you wish, you can get blood testing for HIV at your follow-up appointment. A repeat test is needed 6 weeks and 3 months later in order to know for certain that you have not been infected, and a final test can be done 6 months after the assault. During this time, it is important to use condoms for all voluntary sexual relations.